버킷 림프종 시장 : 인사이트, 역학, 시장 예측(-2034년)

Key Highlights:

• Burkitt lymphoma is a rare malignancy, accounting for only about 1% to 5% of all non-Hodgkin lymphoma cases. Translocation (a type of rearrangement) of a gene called MYC is a hallmark of Burkitt lymphoma, making this an important finding for diagnosis.
• Bispecific-ADC Combination Demonstrates Efficacy in Refractory Burkitt's Lymphoma: A recently published correspondence in The New England Journal of Medicine reports that three patients with chemotherapy-refractory Burkitt's lymphoma achieved complete metabolic responses following treatment with the combination of glofitamab and polatuzumab vedotin.
• In December 2021, the FDA approved RITUXAN (Genentech) in combination with chemotherapy for pediatric patients (>=6 months to <18 years) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL).
• The emerging therapeutic pipeline remains limited, comprising agents such as Sepantronium Bromide (CotheraBio) and ACE1831 (Acepodia Biotech), along with a few other candidates currently being assessed in early-phase clinical trials.

DelveInsight's "Burkitt lymphoma - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Burkitt lymphoma, historical and forecasted epidemiology, as well as the Burkitt lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Burkitt lymphoma market report provides current treatment practices, emerging drugs, Burkitt lymphoma share of individual therapies, and current and forecasted Burkitt lymphoma market size from 2020 to 2034, segmented by seven major markets. The report also covers current Burkitt lymphoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Burkitt Lymphoma Disease Understanding and Treatment Algorithm

Burkitt Lymphoma Overview

Burkitt lymphoma is a highly aggressive, fast-growing B-cell non-Hodgkin lymphoma characterized by translocations involving the MYC oncogene. It has three main subtypes: endemic, sporadic, and immunodeficiency-related, and often presents with rapidly enlarging tumors in the jaw, abdomen, or other extranodal sites. Though rare (about 1-5% of all NHL cases), it is considered a medical emergency due to its rapid progression, but it is also highly responsive to intensive, short-course chemotherapy regimens, often with cure rates exceeding 80% in children when treated promptly.

Burkitt Lymphoma Diagnosis

Burkitt lymphoma is a highly aggressive and rapidly progressing type of non-Hodgkin lymphoma that demands urgent and accurate diagnosis to initiate timely treatment. Since symptoms often appear suddenly and worsen quickly, early detection is vital. Doctors typically begin with a physical examination to look for swollen lymph nodes or abdominal swelling. Diagnostic confirmation is usually made through a biopsy of the affected tissue, while blood tests help assess white blood cell counts, lactate dehydrogenase (LDH) levels, and organ function.

To determine the extent of disease, imaging tests such as CT, PET, or MRI scans are used, along with bone marrow biopsies to check for spread into the bone marrow. In some cases, especially in children or high-risk patients, a lumbar puncture may also be done to evaluate central nervous system involvement. Because Burkitt lymphoma grows so rapidly, treatment is often started immediately after diagnosis, sometimes even before staging is complete. Receiving a prompt and precise evaluation from a lymphoma specialist plays a critical role in improving patient outcomes.

Burkitt Lymphoma Treatment

Since Burkitt lymphoma is very aggressive, the diagnosis of this disease requires urgent hospitalization and the immediate start of therapy. However, Burkitt lymphoma is often very responsive to the currently recommended intensive chemotherapy regimens, and cure rates for this disease remain high.

Treatment options are determined based on low versus high-risk status. The combination of agents used for low and high-risk diseases is similar, but high-risk patients are given additional treatment. All of the treatments used are intensive, using high doses of drugs given frequently.

Specific treatment options for adults include the regimens described below:

• The dose-adjusted EPOCH Regimen
• The Cancer and Leukemia Group B (CALGB) 10002 Regimen
• The CODOX-M Regimen
• The HyperCVAD Regimen

Different combination chemotherapy regimens are used to treat Burkitt lymphoma in children and adolescents. Younger patients tend to have excellent responses to chemotherapy and particularly high cure rates.

Burkitt Lymphoma Epidemiology

The Burkitt lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total prevalent cases of non-Hodgkin lymphoma, diagnosed prevalent cases of burkitt lymphoma, Gender-specific cases of burkitt lymphoma, Age-specific cases of burkitt lymphoma, Subtype-specific cases of burkitt lymphoma, and treatment-eligible pool in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• In the US, Burkitt lymphoma is more prevalent in males, with a 3 to 4:1 male-to-female ratio.
• In children younger than 18, the incidence of Burkitt lymphoma is approximately 3 to 6 cases per 100,000 children annually.
• In the US, the immunodeficiency-associated variant of Burkitt lymphoma occurs at a rate of approximately 22 cases per 100,000 person-years.
• In the UK, approximately 260 individuals are diagnosed with Burkitt lymphoma each year, representing about 2% of all non-Hodgkin lymphoma cases.
• Burkitt lymphoma is the most common form of non-Hodgkin lymphoma in children, while its occurrence in adults is comparatively uncommon.

Burkitt Lymphoma Drug Chapters

Marketed Drugs

RITUXAN (rituximab): Genentech

RITUXAN in combination with chemotherapy is approved for use in pediatric patients aged six months and older with mature B-cell non-Hodgkin lymphoma and mature B-cell acute leukemia (B-AL). Its indication includes the treatment of previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia, when administered in combination with chemotherapy.

Emerging Drugs

Sepantronium Bromide (PC-002): Cothera Bioscience

PC-002 (also known as YM155, sepantronium bromide) is a first-in-class small molecule drug inhibitor of DUB, an enzyme family that removes ubiquitin from cellular proteins otherwise destined for degradation. With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet "undruggable" cancer targets. By inhibiting DUB that stabilizes the Myc protein in cancer cells, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors. PC-002 may potentially target multiple cancer indications involving Myc dysregulation.

PC-002 is currently in Phase II studies for multiple indications, including burkitt lymphoma and DLBCL, and has demonstrated initial efficacy as well as safety in an ongoing monotherapy trial in relapsed and refractory high-grade B-cell lymphoma and Burkitt lymphoma patients with MYC rearrangement.

Drug Class Insight

In the marketed class of drugs, the cornerstone of therapy includes mitogen-activated protein kinase inhibitors such as COTELLIC.

Burkitt Lymphoma Market Outlook

The therapeutic landscape for Burkitt lymphoma remains dominated by intensive, short-course multi-agent chemotherapy regimens, often combined with the anti-CD20 monoclonal antibody rituximab in CD20-positive disease. Pediatric patients, particularly those with localized disease, typically achieve high cure rates, while adult cases, especially in older or comorbid populations, pose greater treatment challenges due to regimen-related toxicity.

Frontline management for advanced-stage Burkitt lymphoma generally involves dose-intensive protocols such as CODOX-M/IVAC or Hyper-CVAD, with rituximab now FDA-approved in pediatric advanced-stage CD20-positive Burkitt lymphoma. For relapsed or refractory disease, therapeutic options are limited and outcomes remain poor, with salvage regimens, high-dose chemotherapy, and hematopoietic stem cell transplantation representing the mainstay. Targeted therapy development is in its infancy, with early clinical evaluations of apoptosis-inducing agents (e.g., sepantronium bromide), cell-based immunotherapies (e.g., ACE1831), and other novel approaches underway. The emerging pipeline is relatively sparse, with most research focused on optimizing existing regimens, incorporating targeted antibodies, and exploring CAR-T cell therapy and bispecific antibodies for refractory settings. This reflects a market still anchored in curative-intent chemotherapy, with gradual movement toward precision and immunotherapy-based strategies for high-risk or treatment-resistant patients.

Burkitt Lymphoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034. The landscape of Burkitt lymphoma treatment has experienced a profound transformation with the uptake of novel drugs.

Burkitt Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, I stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Burkitt lymphoma emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair of the Department of Medicine and Director, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Burkitt lymphoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the Washington University School of Medicine, University Medical Center Hamburg-Eppendorf, and University Graduate School of Medicine, etc., were contacted. Their opinion helps understand and validate Burkitt lymphoma epidemiology and market trends.

Qualitative Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a descriptive overview of Burkitt lymphoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into Burkitt lymphoma epidemiology and treatment.
• Additionally, an all-inclusive account of the current therapies for Burkitt lymphoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Burkitt lymphoma market, historical and forecasted, is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Burkitt lymphoma market.

Burkitt Lymphoma Report Insights

Burkitt Lymphoma Report Insights

• Patient Population
• Therapeutic Approaches
• Burkitt lymphoma Pipeline Analysis
• Burkitt lymphoma Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Burkitt Lymphoma Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage
• Burkitt lymphoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Burkitt Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Analyst Views
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the Burkitt lymphoma market share (%) distribution in 2020, and what would it look like in 2034?
• What would be the Burkitt lymphoma total market size, as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM, and which country will have the largest Burkitt lymphoma market size during the study period (2020-2034)?
• At what CAGR, the burkitt lymphoma market expected to grow at the 7MM level during the study period (2020-2034)?
• What would be the burkitt lymphoma market growth till 2034?
• What are the disease risks, burdens, and unmet needs of Burkitt lymphoma?
• What is the historical burkitt lymphoma patient pool in the United States, the EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of Burkitt lymphoma?
• Among the 7MM, which country would have the most prevalent cases of Burkitt lymphoma?
• At what CAGR is the population expected to grow across the 7MM during the study period (2020-2034)?
• How many companies are developing therapies for the treatment of burkitt lymphoma?
• What are the key collaborations (industry-industry, industry-academia), Mergers and acquisitions, and licensing activities related to Burkitt lymphoma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the 7MM historical and forecasted market of burkitt lymphoma?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the burkitt lymphoma market.
• To understand the future market competition in the burkitt lymphoma market and insightful review of the SWOT analysis of burkitt lymphoma.
• Organize sales and marketing efforts by identifying the best opportunities for burkitt lymphoma in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• To understand the future market competition in burkitt lymphoma.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Burkitt lymphoma

4. Key Events

5. Burkitt Lymphoma Epidemiology and Market Forecast Methodology

6. Burkitt Lymphoma Market Overview at a Glance

• 6.1. Market Share (%) Distribution of Burkitt Lymphoma by Therapies in 2024
• 6.2. Market Share (%) Distribution of Burkitt Lymphoma by Therapies in 2034

7. Disease Background and Overview: Burkitt lymphoma

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Causes
• 7.4. Diagnosis

8. Treatment and Management

• 8.1. Treatment Guidelines and Recommendations

9. Epidemiology and Patient Population of Burkitt Lymphoma in the 7MM

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Prevalent Cases of Burkitt Lymphoma in the 7MM
• 9.4. The United States
  • 9.4.1. Total Prevalent Cases of Non-Hodgkin Lymphoma in the United States
  • 9.4.2. Diagnosed prevalent cases of Burkitt Lymphoma in the United States
  • 9.4.3. Gender-specific Cases of Burkitt Lymphoma in the United States
  • 9.4.4. Age-specific Cases of Burkitt Lymphoma in the United States
  • 9.4.5. Subtype-specific Cases of Burkitt Lymphoma in the United States
  • 9.4.6. Treatment eligible pool
• 9.5. EU4 and the UK
  • 9.5.1. Total Prevalent Cases of Non-Hodgkin Lymphoma in the EU4 and the UK
  • 9.5.2. Diagnosed prevalent cases of Burkitt Lymphoma in the EU4 and the UK
  • 9.5.3. Gender-specific Cases of Burkitt Lymphoma in the EU4 and the UK
  • 9.5.4. Age-specific Cases of Burkitt Lymphoma in the EU4 and the UK
  • 9.5.5. Subtype-specific Cases of Burkitt Lymphoma in the EU4 and the UK
  • 9.5.6. Treatment eligible pool
• 9.6. Japan
  • 9.6.1. Total Prevalent Cases of Non-Hodgkin Lymphoma in Japan
  • 9.6.2. Diagnosed prevalent cases of Burkitt Lymphoma in Japan
  • 9.6.3. Gender-specific Cases of Burkitt Lymphoma in Japan
  • 9.6.4. Age-specific Cases of Burkitt Lymphoma in Japan
  • 9.6.5. Subtype-specific Cases of Burkitt Lymphoma in Japan
  • 9.6.6. Treatment eligible pool

10. Patient Journey

11. Marketed Therapies

• 11.1. Key Competitors
• 11.2. COTELLIC (cobimetinib): Genentech
  • 11.2.1. Product Description
  • 11.2.2. Regulatory milestones
  • 11.2.3. Other Developmental Activity
  • 11.2.4. Clinical Developmental Activities
  • 11.2.5. Safety and efficacy
  • 11.2.6. Analyst Views

12. Emerging Therapies

• 12.1. Key Competitors
• 12.2. Sepantronium Bromide (PC-002): Cothera Bioscience
  • 12.2.1. Product Description
  • 12.2.2. Regulatory milestones
  • 12.2.3. Other Developmental Activity
  • 12.2.4. Clinical Developmental Activities
  • 12.2.5. Safety and efficacy
  • 12.2.6. Analyst Views

13. Burkitt Lymphoma: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Key Market Forecast Assumptions
  • 13.2.1. Cost Assumptions and Rebate
  • 13.2.2. Pricing Trends
  • 13.2.3. Analogue Assessment
  • 13.2.4. Launch Year and Therapy Uptake
• 13.3. Market Outlook
• 13.4. Total Market Size of Burkitt Lymphoma in the 7MM
• 13.5. United States
  • 13.5.1. Total Market Size of Burkitt Lymphoma in the United States
  • 13.5.2. Market Size of Burkitt Lymphoma by Therapies in the United States
• 13.6. EU4 and the UK
  • 13.6.1. Total Market Size of Burkitt Lymphoma in EU4 and the UK
  • 13.6.2. Market size of Burkitt Lymphoma by Therapies in EU4 and the UK
• 13.7. Japan
  • 13.7.1. Total Market Size of Burkitt Lymphoma in Japan
  • 13.7.2. Market Size of Burkitt Lymphoma by Therapies in Japan

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight